7 studies on Mc1r agonist mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This research provides a precise molecular blueprint for designing next-generation melanocortin peptides with high receptor selectivity. For peptide users and developers, this means that compounds could be engineered …
This study highlights a specific, actionable pathway for mitigating the devastating secondary brain injury that follows a hemorrhagic stroke. For researchers and biohackers exploring neuroprotective compounds, it posi…
These findings suggest that administering NDP-MSH during `EVLP` could be a powerful strategy for reconditioning and recovering marginal donor lungs, potentially expanding the pool of organs available for transplantati…
This research reframes Melanotan-II from a controversial tanning agent to a potential topical therapeutic for **melanoma**. For peptide users, this suggests a previously unappreciated anti-cancer mechanism, challengin…
**alpha-MSH and KPV represent a dual-action immunotherapeutic strategy**: simultaneously suppressing pro-inflammatory cytokine cascades and actively inducing antigen-specific tolerance via CTLA4(+)/IL-10(+) T cells — …
**The assumed requirement for cyclic AMP in KPV and alpha-MSH anti-inflammatory action must be reconsidered** — at least in keratinocytes, the operative second messenger appears to be intracellular calcium, not cAMP. …
**Bremelanotide's appearance in a multi-compound clinical-trials digest** places it on the map of agents that had sufficiently advanced development programs to warrant monitoring by major drug-intelligence platforms. …